Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study
Table 1
Patient characteristics.
All patients
Loss of the follow-up
Survivors
Dead
value*
Female
143
17
96
30
0.123
Male
169
13
110
46
Mean/median age (range)
51.3/52 (17–83)
54.9/55
48.3/47.5
58/60 (32–83)
0.104
Subgroup
GCB
104
7
77
20
Non-GC
86
7
49
30
0.023
Unknown
122
16
79
27
Treatment regimen
CHOP based
54
10
25
19
R-CHOP based
258
20
180
58
0.042
Stage
1
75
10
58
7
2
66
4
50
12
3
86
9
49
28
4
85
7
48
30
<0.001
Age
<60
208
19
151
38
≥60
104
11
54
39
<0.001
LDH
Normal
145
17
108
20
High
162
13
93
56
<0.001
Extranodal
<2
220
24
152
44
≥2
92
6
53
33
0.002
Performanceµ
≥70
263
27
183
53
<70
49
3
22
24
<0.001
BMI
No
252
22
173
57
Yes
57
6
32
19
0.090
Bulky mass (>5 cm)
No
179
20
116
43
Yes
129
9
87
33
0.754
IPI
0-1
139
18
106
15
2
68
5
48
15
3
59
5
32
22
4-5
43
2
18
23
<0.001
aaIPI
0
67
7
56
4
1
62
5
46
11
2
53
4
37
12
3
18
2
8
8
0.002
Primary extranodal
No
243
22
153
68
Yes
69
8
53
8
0.005
GC: germinal center B cell. Non-GC: nongerminal center B Cell. LDH: lactate dehydrogenase. BMI: bone marrow involvement at initial diagnosis. Comparison between surviving and dead patients. Karnofsky performance scale.
